Trial Profile
Alternating the Administration of Ixazomib and Lenalidomide as Maintenance Therapy After Autologous Transplant for Treating Multiple Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Ixazomib (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 11 Oct 2023 Planned End Date changed from 1 Jul 2023 to 31 Oct 2024.
- 13 Dec 2022 Results assessing the toxicity and efficacy of this all-oral maintenance regimen presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 10 May 2022 Planned primary completion date changed from 1 May 2022 to 1 Jun 2022.